[go: up one dir, main page]

RU2016136530A3 - - Google Patents

Download PDF

Info

Publication number
RU2016136530A3
RU2016136530A3 RU2016136530A RU2016136530A RU2016136530A3 RU 2016136530 A3 RU2016136530 A3 RU 2016136530A3 RU 2016136530 A RU2016136530 A RU 2016136530A RU 2016136530 A RU2016136530 A RU 2016136530A RU 2016136530 A3 RU2016136530 A3 RU 2016136530A3
Authority
RU
Russia
Application number
RU2016136530A
Other versions
RU2731383C2 (ru
RU2016136530A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2016136530A publication Critical patent/RU2016136530A/ru
Publication of RU2016136530A3 publication Critical patent/RU2016136530A3/ru
Application granted granted Critical
Publication of RU2731383C2 publication Critical patent/RU2731383C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135Compounds containing heavy metals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Inorganic Chemistry (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
RU2016136530A 2014-03-14 2016-09-12 Композиции селеноорганических соединений и способы их применения RU2731383C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2014/029542 WO2015137983A1 (en) 2014-03-14 2014-03-14 Compositions of selenoorganic compounds and methods of use thereof
US14/855,128 US9642874B2 (en) 2014-03-14 2015-09-15 Compositions of selenoorganic compounds and methods of use thereof
US14/855,128 2015-09-15

Publications (3)

Publication Number Publication Date
RU2016136530A RU2016136530A (ru) 2018-03-16
RU2016136530A3 true RU2016136530A3 (ru) 2019-11-25
RU2731383C2 RU2731383C2 (ru) 2020-09-02

Family

ID=54072241

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2016133469A RU2665135C2 (ru) 2014-03-14 2014-03-14 Композиции селеноорганических соединений и способы их применения
RU2016136530A RU2731383C2 (ru) 2014-03-14 2016-09-12 Композиции селеноорганических соединений и способы их применения

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2016133469A RU2665135C2 (ru) 2014-03-14 2014-03-14 Композиции селеноорганических соединений и способы их применения

Country Status (16)

Country Link
US (3) US10201559B2 (ru)
EP (1) EP3116511B1 (ru)
JP (2) JP6313479B2 (ru)
KR (3) KR102448455B1 (ru)
CN (3) CN106456658A (ru)
AU (4) AU2014386236B2 (ru)
BR (1) BR112016020233B1 (ru)
CA (1) CA2940283C (ru)
DK (2) DK3116511T3 (ru)
HU (2) HUE051713T2 (ru)
IL (1) IL247312A0 (ru)
MX (2) MX2016011897A (ru)
PE (1) PE20211069A1 (ru)
PT (1) PT3116511T (ru)
RU (2) RU2665135C2 (ru)
WO (2) WO2015137983A1 (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102448455B1 (ko) 2014-03-14 2022-09-28 올텍 법인회사 셀레노유기 화합물의 조성물 및 이의 사용 방법
WO2016160594A1 (en) 2015-03-27 2016-10-06 The Research Foundation For The State University Of New York Methods and materials for reducing amyloid beta levels within a mammal
WO2017048252A1 (en) * 2015-09-15 2017-03-23 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof
KR102054640B1 (ko) * 2015-09-24 2019-12-11 서울대학교산학협력단 아데노신 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
WO2017160678A1 (en) * 2016-03-14 2017-09-21 Mitogenetics, Llc Materials and methods for treating hypoxic conditions
CN120647702A (zh) * 2017-05-19 2025-09-16 全技术公司 药剂、组合物及其相关方法
EP3661600A4 (en) 2017-10-23 2021-08-11 Epitracker, Inc. FATTY ACID ANALOGS AND ITS USE IN THE TREATMENT OF DISEASES RELATED TO METABOLISM SYNDROME
KR102083180B1 (ko) 2017-11-09 2020-03-02 서울대학교산학협력단 셀레노사마필린 a와 그 유도체, 이의 제조방법, 및 이를 유효성분으로 포함하는 암 예방 및 치료용 조성물
WO2019093699A1 (ko) * 2017-11-09 2019-05-16 서울대학교 산학협력단 셀레노사마필린 a와 그 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 예방 및 치료용 조성물
CN108484690B (zh) * 2018-05-16 2021-04-30 新乡拓新药业股份有限公司 一种1,2,3-三-O-乙酰基-5-脱氧-β-D-核糖的制备方法
AU2019274431B2 (en) 2018-05-23 2025-03-13 Epitracker, Inc. Compositions and methods for diagnosis and treatment of conditions related to the quality of aging and longevity
EP3908374A4 (en) 2019-01-09 2022-12-28 Epitracker, Inc. COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES
JP7404382B2 (ja) 2019-03-04 2023-12-25 エピトラッカー インコーポレイテッド 脂肪酸アナログ、ならびに認知機能障害、行動症状および慢性疼痛の処置におけるそれらの使用
CN111543641A (zh) * 2020-04-27 2020-08-18 江苏惠利生物科技有限公司 一种提高l-硒-甲基硒代半胱氨酸稳定性以及生物利用率的方法
EP4185306A4 (en) * 2020-07-23 2024-11-06 Purdue Research Foundation NOTCH SIGNAL INHIBITORS FOR THE TREATMENT OF OBESITY AND METABOLIC DISEASES
WO2023080939A1 (en) 2021-11-03 2023-05-11 Epitracker, Inc. Pentadecanoylcarnitine for treatment of conditions related to the quality of aging and longevity
JP2023076373A (ja) * 2021-11-22 2023-06-01 マルサンアイ株式会社 アミロイドβ凝集抑制剤とこれを含む医薬組成物および飲食品、ネプリライシン産生促進剤およびγ-セクレターゼ産生抑制剤
CN116333302B (zh) * 2023-03-31 2024-09-10 中南大学 一种稳定持久抗氧化纳米点及其在二型糖尿病中的应用
CN116421618B (zh) * 2023-06-15 2023-09-29 暨南大学 Se@NADH的制备方法及其在脊髓损伤治疗中的应用
US12285412B1 (en) 2024-12-27 2025-04-29 Imam Mohammad Ibn Saud Islamic University Organoselenium benzimidazole compounds for treating cancer

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5463092A (en) 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US7517858B1 (en) 1995-06-07 2009-04-14 The Regents Of The University Of California Prodrugs of pharmaceuticals with improved bioavailability
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
AU7361400A (en) 1999-09-08 2001-04-10 Metabasis Therapeutics, Inc. Prodrugs for liver specific drug delivery
MXPA02005490A (es) 1999-12-03 2004-09-10 Univ California San Diego Compuestos de fosfonato.
AU784462B2 (en) 2000-03-31 2006-04-06 Purdue Research Foundation Phosphoramidate prodrugs
TWI332956B (en) 2002-04-26 2010-11-11 Gilead Sciences Inc Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds
JP4332496B2 (ja) 2002-05-13 2009-09-16 メタバシス・セラピューティクス・インコーポレイテッド Pmeaおよびpmpa環生成合成
IL164809A0 (en) 2002-05-13 2005-12-18 Metabasis Therapeutics Inc Novel phosphonic acid basdrugs of pmea and its analogues
PL214402B1 (pl) * 2003-08-11 2013-07-31 Tomasz Byrski Zastosowanie selenu albo jego zwiazku do otrzymywania srodka do obnizania odziedziczonego ryzyka zachorowania na raka piersi lub jajnika
WO2005023274A1 (en) * 2003-09-05 2005-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
EP1652519A1 (en) 2004-10-28 2006-05-03 Tamie Nasu Seleniferous composition for producing antioxidase in vivo
JP2006151965A (ja) 2004-10-28 2006-06-15 Mi Tec:Kk セレン含有組成物及びその製法
CA2598821C (en) * 2004-12-31 2011-05-31 Heonjoong Kang Organoselenium containing compounds and their use
US20060198906A1 (en) 2005-03-07 2006-09-07 Sami Labs Limited Compositions and Method to Increase Serum Levels of HDL cholesterol and Lower the Risk of Cardiovascular Disease
US20070077238A1 (en) 2005-10-04 2007-04-05 Teo Alex Y Production of organic and inorganic selenium compounds by lactic acid bacteria
CA2524551C (en) * 2005-10-14 2014-12-16 Alltech, Inc. Use of selenium yeasts in the treatment of alzheimer's disease
US8865763B2 (en) 2005-10-14 2014-10-21 Alltech, Inc. Methods and compositions for altering cell function
AU2005227420B2 (en) 2005-10-14 2013-05-09 Alltech, Inc. Method and compositions for altering cell function
US20080004255A1 (en) 2005-10-14 2008-01-03 Alltech, Inc. Methods and compositions for altering cell function
CN101045048B (zh) * 2006-03-27 2011-05-18 中国科学院上海生命科学研究院 线粒体营养素组合物的应用
WO2007127273A2 (en) * 2006-04-24 2007-11-08 Alltech, Inc. Methods and compositions for altering cell function
EP2192905A4 (en) * 2007-08-29 2010-11-10 Adam Lubin METHOD FOR SELECTIVE THERAPY OF DISEASE
US20110177140A1 (en) * 2007-08-31 2011-07-21 Rainer Voegeli 4-amidino benzylamines for cosmetic and/or dermatological use
EP2220208A4 (en) * 2007-11-23 2010-12-29 Rappaport Family Inst For Res USE OF HAPTOGLOBIN ENTYPIZATION FOR THE DIAGNOSIS AND TREATMENT OF CARDIOVASCULAR DISEASES
CN101289495A (zh) * 2008-05-23 2008-10-22 浙江大学 含硒五肽化合物及其应用
RU2012120785A (ru) * 2009-10-22 2013-11-27 ПРОПАНК ПиТиУай ЛТД Фармацевтические композиции
JP5510302B2 (ja) * 2010-12-15 2014-06-04 トヨタ紡織株式会社 接続部材、その製造方法及び接続構造体
RU2605287C2 (ru) * 2011-04-01 2016-12-20 Иасомай АБ Новая комбинация, содержащая n-ацетил-l-цистеин, и ее применение
US20150057243A1 (en) 2012-04-02 2015-02-26 Northern University Compositions and Methods for the Inhibition of Methyltransferases
NL2010222C2 (en) * 2013-02-01 2014-08-04 Conradus Ghosal Gho Composition and method for generating a desired cell type and/or tissue type from hair follicular stem cells.
MX359626B (es) * 2013-03-15 2018-10-01 Alltech Inc Composiciones que comprenden selenio y uso de las mismas para el tratamiento y prevención de enfermedades o afecciones asociadas con disfunción mitocondrial.
KR102448455B1 (ko) 2014-03-14 2022-09-28 올텍 법인회사 셀레노유기 화합물의 조성물 및 이의 사용 방법
US20160000136A1 (en) * 2014-07-02 2016-01-07 Hamilton Beach Brands, Inc. Juice Extractor
US20160090397A1 (en) 2014-09-30 2016-03-31 Northeastern University Se-Adenosyl-L-Selenohomocysteine Selenoxide As A Modulator Of Methyltransferase And Other Activities

Also Published As

Publication number Publication date
NZ723402A (en) 2024-11-29
US20160045533A1 (en) 2016-02-18
AU2016222315B2 (en) 2022-08-04
CN106456658A (zh) 2017-02-22
DK3116511T3 (da) 2020-11-23
IL247312A0 (en) 2016-09-29
CA2940283A1 (en) 2015-09-17
DK3144001T3 (da) 2021-11-15
KR102448455B1 (ko) 2022-09-28
KR20170032862A (ko) 2017-03-23
BR102016021058A2 (pt) 2017-05-30
AU2019246818A1 (en) 2019-10-31
RU2665135C2 (ru) 2018-08-28
US10201559B2 (en) 2019-02-12
EP3116511A4 (en) 2017-10-18
CN106822168A (zh) 2017-06-13
US10201558B2 (en) 2019-02-12
JP2017512828A (ja) 2017-05-25
WO2015137983A1 (en) 2015-09-17
AU2014386236A1 (en) 2016-09-01
PT3116511T (pt) 2020-11-19
RU2731383C2 (ru) 2020-09-02
NZ723233A (en) 2020-10-30
JP2017078056A (ja) 2017-04-27
CN113694074A (zh) 2021-11-26
RU2016136530A (ru) 2018-03-16
AU2022204588A1 (en) 2022-07-21
AU2019246818B2 (en) 2021-02-25
CA2940283C (en) 2021-03-30
US9642874B2 (en) 2017-05-09
EP3116511A1 (en) 2017-01-18
BR112016020233A2 (ru) 2017-08-15
MX2016011898A (es) 2018-03-12
AU2014386236B2 (en) 2019-07-11
JP7009053B2 (ja) 2022-01-25
MX2016011897A (es) 2017-04-27
WO2017048253A1 (en) 2017-03-23
US20160361338A1 (en) 2016-12-15
PE20211069A1 (es) 2021-06-09
BR112016020233B1 (pt) 2022-07-19
KR20210104070A (ko) 2021-08-24
HUE051713T2 (hu) 2021-03-29
JP6313479B2 (ja) 2018-04-18
US20160082033A1 (en) 2016-03-24
KR102764247B1 (ko) 2025-02-07
KR20160125989A (ko) 2016-11-01
KR102466389B1 (ko) 2022-11-11
CN106822168B (zh) 2020-11-27
EP3116511B1 (en) 2020-08-26
AU2016222315A1 (en) 2017-03-30
RU2016133469A (ru) 2018-04-17
HUE056172T2 (hu) 2022-01-28

Similar Documents

Publication Publication Date Title
BR112016017520A2 (ru)
BR112016016951A2 (ru)
BR112016016478A2 (ru)
BR112016016978A2 (ru)
BR112016018948A2 (ru)
BR112016018868A2 (ru)
BR112016018384A2 (ru)
BR112016018582A2 (ru)
RU2016136530A3 (ru)
BR112016018556A2 (ru)
BR112016015385A2 (ru)
BR112016018865A2 (ru)
BR112016008129A2 (ru)
BR112016016364A2 (ru)
BR112016014460A2 (ru)
BR112016017713A2 (ru)
BR112016016298A2 (ru)
BR112016018944A2 (ru)
BR112016015645A2 (ru)
BR112016000228A2 (ru)
BR112016016534A2 (ru)
BR112016016601A2 (ru)
BR112016015552A2 (ru)
BR112016016575A2 (ru)
BR112016015797A2 (ru)